ESTRO 2024 - Abstract Book

S1843

Clinical - Mixed sites, palliation

ESTRO 2024

Conclusion:

This is the first joint ESMO-ESTRO initiative to provide clinicians with multidisciplinary, evidence-based, hands-on Delphi consensus recommendations on the safety of combining targeted therapies and immunotherapy with RT. The recommendations are expected to aid in daily clinical decision making and to reduce the risk of both undertreatment and unexpected toxicity.

Keywords: Targeted therapies, immunotherapy, toxicity

380

Mini-Oral

Clinical experience with same-day delivery of adaptive palliative radiotherapy without a planning CT

Koen J Nelissen 1,2 , Eva Versteijne 1,2 , Suresh Senan 1,2 , Ben J Slotman 1,2 , Wilko F.A.R. Verbakel 1,2,3

1 Amsterdam UMC location Vrije Universiteit Amsterdam, Radiation Oncology, Amsterdam, Netherlands. 2 Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, Netherlands. 3 Varian Medical Systems, Radiotherapy Soluctions, Palo Alto, USA

Purpose/Objective:

Radiotherapy for painful bone metastases is most effective when delivered shortly after referral to obtain rapid pain relief. Same-day palliative radiotherapy can improve clinical efficiency, lower barriers for access to healthcare, reduce costs, and limit disruption to planned systemic treatments. We previously reported on the FAST-METS trial 1 ,